Protein interactors of 3-O sulfated heparan sulfates in human MCI and age-matched control cerebrospinal fluid.


Journal

Scientific data
ISSN: 2052-4463
Titre abrégé: Sci Data
Pays: England
ID NLM: 101640192

Informations de publication

Date de publication:
06 03 2023
Historique:
received: 06 09 2022
accepted: 07 02 2023
entrez: 6 3 2023
pubmed: 7 3 2023
medline: 9 3 2023
Statut: epublish

Résumé

Heparan sulfates (HS) proteoglycans are commonly found on the cell surface and mediate many processes. Binding of HS ligands is determined by the sulfation code on the HS chain that can be N-/2-O/6-O- or 3-O-sulfated, generating heterogenous sulfation patterns. 3-O sulfated HS (3S-HS) play a role in several (patho)physiological processes such as blood coagulation, viral pathogenesis and binding and internalization of tau in Alzheimer's disease. However, few 3S-HS-specific interactors are known. Thus, our insight into the role of 3S-HS in health and disease is limited, especially in the central nervous system. Using human CSF, we determined the interactome of synthetic HS with defined sulfation patterns. Our affinity-enrichment mass spectrometry studies expand the repertoire of proteins that may interact with (3S-)HS. Validating our approach, ATIII, a known 3S-HS interactor, was found to require GlcA-GlcNS6S3S for binding, similar to what has been reported. Our dataset holds novel, potential HS and 3S-HS protein ligands, that can be explored in future studies focusing on molecular mechanisms that depend on 3S-HS in (patho)physiological conditions.

Identifiants

pubmed: 36879013
doi: 10.1038/s41597-023-02009-1
pii: 10.1038/s41597-023-02009-1
pmc: PMC9986659
doi:

Substances chimiques

Heparitin Sulfate 9050-30-0
Ligands 0
Sulfates 0

Types de publication

Dataset Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

121

Subventions

Organisme : Agentschap Innoveren en Ondernemen (Flanders Innovation & Entrepreneurship)
ID : HBC.2017.0231

Informations de copyright

© 2023. The Author(s).

Références

Nat Genet. 2022 Apr;54(4):412-436
pubmed: 35379992
Nat Med. 2020 May;26(5):769-780
pubmed: 32284590
J Cell Biochem. 2006 Apr 15;97(6):1241-58
pubmed: 16315317
Cell. 1999 Oct 1;99(1):13-22
pubmed: 10520990
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Matrix Biol. 2007 Jul;26(6):442-55
pubmed: 17482450
Clin Proteomics. 2020 May 29;17:19
pubmed: 32514259
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47
pubmed: 23898162
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Nov 15;1068-1069:78-83
pubmed: 29031112
PLoS One. 2018 Jan 11;13(1):e0189209
pubmed: 29324744
Nat Genet. 2019 Mar;51(3):404-413
pubmed: 30617256
Front Aging Neurosci. 2014 May 20;6:93
pubmed: 24904407
J Biol Chem. 2012 Jun 15;287(25):20774-83
pubmed: 22547069
J Biol Chem. 1999 Jul 30;274(31):21511-4
pubmed: 10419453
Mol Syst Biol. 2020 Jun;16(6):e9356
pubmed: 32485097
J Mol Biol. 2009 May 1;388(2):310-26
pubmed: 19289127
Neurology. 2009 Dec 1;73(22):1914-22
pubmed: 19949037
Brain. 2015 May;138(Pt 5):1339-54
pubmed: 25842390
J Biol Chem. 2007 Aug 17;282(33):24416-29
pubmed: 17588944
J Neurosci. 2011 Feb 2;31(5):1644-51
pubmed: 21289173
Mol Cell Proteomics. 2015 Jan;14(1):120-35
pubmed: 25363814
ACS Chem Biol. 2016 Apr 15;11(4):971-80
pubmed: 26731579
Glycobiology. 2005 Oct;15(10):982-93
pubmed: 15944372
J Biol Chem. 1999 Feb 19;274(8):5170-84
pubmed: 9988767
Angew Chem Int Ed Engl. 2020 Jan 27;59(5):1818-1827
pubmed: 31692167
J Mol Biol. 2008 Sep 19;381(5):1213-23
pubmed: 18602404
IEEE Trans Vis Comput Graph. 2014 Dec;20(12):1983-92
pubmed: 26356912
BMC Mol Cell Biol. 2022 Dec 24;23(1):61
pubmed: 36564747
J Histochem Cytochem. 2012 Dec;60(12):898-907
pubmed: 23042481
Sci Rep. 2020 Nov 5;10(1):19114
pubmed: 33154448

Auteurs

Andreia Ferreira (A)

Janssen Research & Development, a Division of Janssen Pharmaceutica N.V., 2340, Beerse, Belgium.
VIB-UGent Center for Medical Biotechnology, B-9052 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9052, Ghent, Belgium.

Evy Timmerman (E)

VIB-UGent Center for Medical Biotechnology, B-9052 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9052, Ghent, Belgium.
VIB Proteomics Core, B-9000 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9000, Ghent, Belgium.

An Staes (A)

VIB-UGent Center for Medical Biotechnology, B-9052 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9052, Ghent, Belgium.

Marnik Vuylsteke (M)

Gnomixx, B-9090, Melle, Belgium.

Louis De Muynck (L)

Janssen Research & Development, a Division of Janssen Pharmaceutica N.V., 2340, Beerse, Belgium. ldemuync@its.jnj.com.

Kris Gevaert (K)

VIB-UGent Center for Medical Biotechnology, B-9052 Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, B-9052, Ghent, Belgium. kris.gevaert@vib-ugent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH